The potential of miR-153 as aggressive prostate cancer biomarker

Gilyazova, I. R.; Ivanova, Elizaveta; Sinelnikov, Mikhail Y.; Павлов, В. Н.; Хуснутдинова, Э. К.; Gareev, Ilgiz; Beilerli, Aferin; Mikhaleva, L.M.; Liang, Yong

doi:10.1016/j.ncrna.2022.10.002

Cited by 3 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Researchers identified the prognostic ability of miR‐153 with respect to the development of metastases (AUC = 0.85; 95% CI 0.75–0.95; sensitivity = 0.72, specificity = 0.86)). [ 117 ]…”

Section: Prognostic and Predictive Epigenetic Biomarkersmentioning

confidence: 99%

Epigenetics as a Key Factor in Prostate Cancer

Enikeeva,

Rafikova,

Sharifyanova

et al. 2024

Advanced Biology

Self Cite

View full text Add to dashboard Cite

Nowadays, prostate cancer is one of the most common forms of malignant neoplasms in men all over the world. Against the background of increasing incidence, there is a high mortality rate from prostate cancer, which is associated with an inadequate treatment strategy. Such a high prevalence of prostate cancer requires the development of methods that can ensure early detection of the disease, improve the effectiveness of treatment, and predict the therapeutic effect. Under these circumstances, it becomes crucial to focus on the development of effective diagnostic and therapeutic approaches. Due to the development of molecular genetic methods, a large number of studies have been accumulated on the role of epigenetic regulation of gene activity in cancer development, since it is epigenetic changes that can be detected at the earliest stages of cancer development. The presence of epigenetic aberrations in tumor tissue and correlations with drug resistance suggest new therapeutic approaches. Detection of epigenetic alterations such as CpG island methylation, histone modification, and microRNAs as biomarkers will improve the diagnosis of the disease, and the use of these strategies as targets for therapy will allow for greater personalization of prostate cancer treatment.

show abstract

“…Researchers identified the prognostic ability of miR‐153 with respect to the development of metastases (AUC = 0.85; 95% CI 0.75–0.95; sensitivity = 0.72, specificity = 0.86)). [ 117 ]…”

Section: Prognostic and Predictive Epigenetic Biomarkersmentioning

confidence: 99%

Epigenetics as a Key Factor in Prostate Cancer

Enikeeva,

Rafikova,

Sharifyanova

et al. 2024

Advanced Biology

Self Cite

View full text Add to dashboard Cite

show abstract

Ferroptosis‐Related LncRNA BCRP3 Promotes the Proliferation and Migration of Prostate Cancer

Zhou,

Gu,

Zhao

et al. 2024

European Journal of Cancer Care

View full text Add to dashboard Cite

Background: Long noncoding RNAs (lncRNAs) are reported that play an important role in regulating tumorigenesis. This study aims to develop a ferroptosis‐related lncRNA gene signature for predicting biochemical recurrence of prostate cancer (PCa) and prove a functional lncRNA BCRP3 as a promotor toward PCa progression.Methods: The ferroptosis‐related lncRNA were identified by interoperating the databases of The Cancer Genome Atlas (TCGA) and FerrDb. A predictive model for biochemical recurrence of PCa was established based on the LASSO Cox regression. Kaplan–Meier cures were applied in the measurement of the impact on patients’ survival caused by key lncRNAs. Meanwhile, the molecular assays of CCK8, EdU, wound healing, and Transwell were conducted to evaluate the tumor‐suppressive effect of BCRP3 in vitro.Results: This study presented that 17 differentially expressed ferroptosis‐related lncRNAs were confirmed and further screened out 9 key lncRNAs for the establishment of risk model. The nomogram involved the risk model was also proved with an excellent predictive performance toward 1‐, 3‐, and 5‐year survival with the area of curves (AUC) as 0.77, 0.79, and 0.65 separately. Notably, the lncRNA BCRP3 was significantly correlated with the survival of PCa patients based on multivariate Cox regression. Additionally, downregulation of BCRP3 effectively inhibited the proliferation, migration, and invasion of PC3 cells which further proved its anti‐tumor function.Conclusion: We developed a ferroptosis‐related lncRNA risk model for predicting biochemical recurrence, which assisting in the clinical therapy of patients with PCa.

show abstract

Inhibiting SHP2 reduces glycolysis, promotes microglial M1 polarization, and alleviates secondary inflammation following spinal cord injury in a mouse model

Ding,

Chen,

Zhao

et al. 2024

Neural Regeneration Research

View full text Add to dashboard Cite

Reducing the secondary inflammatory response, which is partly mediated by microglia, is a key focus in the treatment of spinal cord injury. Src homology 2-containing protein tyrosine phosphatase 2 (SHP2), encoded by PTPN11, is widely expressed in the human body and plays a role in inflammation through various mechanisms. Therefore, SHP2 is considered a potential target for the treatment of inflammation-related diseases. However, its role in secondary inflammation after spinal cord injury remains unclear. In this study, SHP2 was found to be abundantly expressed in microglia at the site of spinal cord injury. Inhibition of SHP2 expression using siRNA and SHP2 inhibitors attenuated the microglial inflammatory response in an in vitro lipopolysaccharide-induced model of inflammation. Notably, after treatment with SHP2 inhibitors, mice with spinal cord injury exhibited significantly improved hind limb locomotor function and reduced residual urine volume in the bladder. Subsequent in vitro experiments showed that, in microglia stimulated with lipopolysaccharide, inhibiting SHP2 expression promoted M2 polarization and inhibited M1 polarization. Finally, a co-culture experiment was conducted to assess the effect of microglia treated with SHP2 inhibitors on neuronal cells. The results demonstrated that inflammatory factors produced by microglia promoted neuronal apoptosis, while inhibiting SHP2 expression mitigated these effects. Collectively, our findings suggest that SHP2 enhances secondary inflammation and neuronal damage subsequent to spinal cord injury by modulating microglial phenotype. Therefore, inhibiting SHP2 alleviates the inflammatory response in mice with spinal cord injury and promotes functional recovery postinjury.

show abstract

The potential of miR-153 as aggressive prostate cancer biomarker

Cited by 3 publications

References 42 publications

Epigenetics as a Key Factor in Prostate Cancer

Epigenetics as a Key Factor in Prostate Cancer

Ferroptosis‐Related LncRNA BCRP3 Promotes the Proliferation and Migration of Prostate Cancer

Inhibiting SHP2 reduces glycolysis, promotes microglial M1 polarization, and alleviates secondary inflammation following spinal cord injury in a mouse model

Contact Info

Product

Resources

About